A good immunotherapies deal may be all that is needed to ignite the share price. At the moment, the market is treating that business as ceased, with no value. For example, the HPV phase I trial has received funding from the Qld Government and, as of the AGM, had ethics approval. Yet, it hasnt commenced. It hasnt commenced due to logistics or maybe its waiting on a deal in which case whoever takes over responsibility for immunotherapies can have its input into the HPV trial and design?
Expecting what, when?, page-5
-
- There are more pages in this discussion • 284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |